STUDIES OF THE HER-2/NEU PROTO-ONCOGENE IN HUMAN-BREAST AND OVARIAN-CANCER
STUDIES OF THE HER-2/NEU PROTO-ONCOGENE IN HUMAN-BREAST AND OVARIAN-CANCER
复制标题
DOI：
10.1126/science.2470152
复制
发表时间：
1989-05-12
期刊：
影响因子：
56.9
通讯作者：
PRESS, MF
中科院分区：
文献类型：
--
作者：
SLAMON, DJ;GODOLPHIN, W;PRESS, MF
乳腺癌和卵巢癌占发生在妇女身上的所有癌症的三分之一，两者加起来造成大约四分之一的女性癌症相关死亡。HER-2/ new原癌基因在25%至30%的人类原发性乳腺癌中扩增，这种改变与疾病行为有关。在本报告中，我们发现HER-2/neu在乳腺癌和卵巢癌中的生物学相似性，包括相似的扩增发生率、扩增与过表达之间的直接关系、有证据表明在没有扩增的情况下也会发生过表达的肿瘤，以及基因改变与临床结果之间的关联。对该基因及其产物（RNA和蛋白质）的全面研究同时在大量的两种肿瘤类型上进行。该分析确定了用于评估这些疾病中HER-2/neu的各种方法（Southern, Northern, and Western blots，以及免疫组织化学）的几个潜在缺陷，并提供了在研究人体组织中的基因或基因产物时应注意的事项。这些数据进一步支持了HER-2/neu基因可能参与某些人类癌症发病机制的观点。
Carcinoma of the breast and ovary account for one-third of all cancers occurring in women and together are responsible for approximately one-quarter of cancer-related deaths in females. The HER-2/neu proto-oncogene is amplified in 25 to 30 percent of human primary breast cancers and this alteration is associated with disease behavior. In this report, several similarities were found in the biology of HER-2/neu in breast and ovarian cancer, including a similar incidence of amplication, a direct correlation between amplification and over-expression, evidence of tumors in which overexpression occurs without amplification, and the association between gene alteration and clinical outcome. A comprehensive study of the gene and its products (RNA and protein) was simultaneously performed on a large number of both tumor types. This analysis identified several potential shortcomings of the various methods used to evaluate HER-2/neu in these diseases (Southern, Northern, and Western blots, and immunohistochemistry) and provided information regarding considerations that should be addressed when studying a gene or gene product in human tissue. The data presented further support the concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers.